ReviewFrontiers in immunology2022
The immune responses to different
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 15 citations in OpenAlex.
- The role of probiotics in restoring and maintaining vaginal microbiome health: a review.Infection and immunity · 2026Review
- Anti-inflammatory and anti-bacterial potentials of Caryota mitis L. leaves extract in urothelial LPS-induced inflammation and UTI pathogens.Archives of microbiology · 2026Article
- Stem cell-derived exosomes in complicated urinary tract infections: immunomodulatory mechanisms and potential therapeutic strategies for urothelial repair.Stem cell research & therapy · 2025Review
- Rapid and accurate testing for urinary tract infection: new clothes for the emperor.Clinical microbiology reviews · 2025Review
- Urinary tract infections: pathogenesis, host susceptibility and emerging therapeutics.Nature reviews. Microbiology · 2025Review
- Nonsurgical resolution of renal cortical abscesses in a dog with multidrug-resistantOpen veterinary journal · 2025Article
- Current state of training needs and programs for infection control liaison nurses.Frontiers in medicine · 2025Review
- The Prevalence and Association of Different Uropathogens Detected by M-PCR with Infection-Associated Urine Biomarkers in Urinary Tract Infections.Research and reports in urology · 2024Article
- Elevated UTI Biomarkers in Symptomatic Patients with Urine Microbial Densities of 10,000 CFU/mL Indicate a Lower Threshold for Diagnosing UTIs.Diagnostics (Basel, Switzerland) · 2023Article
- Cycle Biodynamics of Women's Microbiome in the Urinary and Reproductive Systems.Journal of clinical medicine · 2023Review
- Urinary Tract Infections: The Current Scenario and Future Prospects.Pathogens (Basel, Switzerland) · 2023Review
- Beyond the usual suspects: emerging uropathogens in the microbiome age.Frontiers in urology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Urinary tract infection (UTI) caused by uropathogens is the most common infectious disease and significantly affects all aspects of the quality of life of the patients. However, uropathogens are increasingly becoming antibiotic-resistant, which threatens the only effective treatment option available-antibiotic, resulting in higher medical costs, prolonged hospital stays, and increased mortality. Currently, people are turning their attention to the immune responses, hoping to find effective immunotherapeutic interventions which can be alternatives to the overuse of antibiotic drugs. Bladder infections are caused by the main nine uropathogens and the bladder executes different immune responses depending on the type of uropathogens. It is essential to understand the immune responses to diverse uropathogens in bladder infection for guiding the design and development of immunotherapeutic interventions. This review firstly sorts out and comparatively analyzes the immune responses to the main nine uropathogens in bladder infection, and summarizes their similarities and differences. Based on these immune responses, we innovatively propose that different microbial bladder infections should adopt corresponding immunomodulatory interventions, and the same immunomodulatory intervention can also be applied to diverse microbial infections if they share the same effective therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.